RxDoctor Payments Data

Jeffrey Lawrence

Family Medicine · Edmond, OKNPI 1790009736

Payments from drug & device makers

$6,950in general payments, 2019–2025

Across 479 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$881
  • AbbVie$810
  • GSK$797
  • Novo Nordisk$682
  • AstraZeneca$479
  • Takeda Pharmaceuticals U.S.A., Inc.$353
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,940100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,950 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$135,617
Medicare patients
425
Services billed
1,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$129,954
JardianceEmpagliflozin73$91,211
EliquisApixaban64$80,325
MounjaroTirzepatide41$46,497
TrulicityDulaglutide26$39,858
FarxigaDapagliflozin Propanediol36$36,294
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$24,256
MyrbetriqMirabegron22$21,031
XareltoRivaroxaban15$11,965
JanuviaSitagliptin Phosphate13$10,994
LivaloPitavastatin Calcium17$10,093
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$9,668
Atorvastatin Calcium793$9,383
Omeprazole255$4,740
Colestipol Hcl60$4,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$682$129,95496 claims
Boehringer IngelheimJardiance$70$91,21173 claims
Lilly USA, LLCMounjaro, Trulicity$347$86,35467 claims
PfizerEliquis$881$80,32564 claims
AstraZenecaFarxiga$479$36,29436 claims
GSKTrelegy Ellipta$797$24,25621 claims
Astellas Pharma US IncMyrbetriq$223$21,03122 claims
Johnson & JohnsonXarelto$12$11,96515 claims
MerckJanuvia$181$10,99413 claims
Kowa Pharmaceuticals America, Inc.Livalo$16$10,09317 claims
AbbVieSynthroid$810$1,55912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →